Comparison of microsomal prostaglandin E synthase-1 deletion and COX-2 inhibition in acute cardiac ischemia in mice

Prostaglandins and Other Lipid Mediators

Volumn 90, Issue 1-2, 2009, Pages 21-25

  Wu, Dongmei ^a   Mennerich, Detlev ^b   Arndt, Kirsten ^b   Sugiyama, Kenji ^c   Ozaki, Naoko ^c   Schwarz, Karoline ^b   Wei, Jianqin ^d   Wu, Heng ^a   Bishopric, Nanette H ^d   Doods, Henri ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c Boehringer Ingelheim Pharmaceuticals Inc   (Japan)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclooxygenase 2; Microsomal prostaglandin E synthase 1; Myocardial ischemia; Prostaglandin E2

Indexed keywords

CELECOXIB; CREATINE KINASE; CYCLOOXYGENASE 2; PROSTAGLANDIN E SYNTHASE; TROPONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GENE DELETION; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; LEFT CORONARY ARTERY; MICROSOME; MOUSE; NONHUMAN;

ANIMALS; CORONARY OCCLUSION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; GENE DELETION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INTRAMOLECULAR OXIDOREDUCTASES; MICE; MICROSOMES; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; RNA, MESSENGER;

EID: 70350011904     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2009.06.006     Document Type: Article

References (39)

1. Vane J.R., Bakhle Y.S., and Botting R.M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38 (1998) 97-120
2. Fitzpatrick F.A. Cyclooxygenase enzymes: regulation and function. Curr Pharm Des 10 (2004) 577-588
3. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
4. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
5. Samuelsson B., Morgenstern R., and Jakobsson P.J. Membrane prostaglandin e synthase-1: a novel therapeutic target. Pharmacol Rev 59 (2007) 207-224
6. Claveau D., Sirinyan M., Guay J., et al. Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model. J Immunol 170 (2003) 4738-4744
7. Kamei D., Yamakawa K., Takegoshi Y., et al. Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin e synthase-1. J Biol Chem 279 (2004) 33684-33695
8. Park J.Y., Pillinger M.H., and Abramson S.B. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol 119 (2006) 229-240
9. Trebino C.E., Stock J.L., Gibbons C.P., et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci USA 100 (2003) 9044-9049
10. Cheng Y., Wang M., Yu Y., Lawson J., Funk C.D., and Fitzgerald G.A. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 116 (2006) 1391-1399
11. Jia Z., Zhang A., Zhang H., Dong Z., and Yang T. Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion. Circ Res 99 (2006) 1243-1251
12. Yang T. Microsomal prostaglandin E synthase-1 and blood pressure regulation. Kidney Int 72 (2007) 274-278
13. Wang M., Lee E., Song W., et al. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation 117 (2008) 1302-1309
14. Wang M., Zukas A.M., Hui Y., Ricciotti E., Pure E., and FitzGerald G.A. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci USA 103 (2006) 14507-14512
15. Ikeda-Matsuo Y., Ota A., Fukada T., Uematsu S., Akira S., and Sasaki Y. Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury. Proc Natl Acad Sci USA 103 (2006) 11790-11795
16. Degousee N., Fazel S., Angoulvant D., et al. Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation 117 (2008) 1701-1710
17. Nakatani Y., Hokonohara Y., Kakuta S., Sudo K., Iwakura Y., and Kudo I. Knockout mice lacking cPGES/p23, a constitutively expressed PGE2 synthetic enzyme, are peri-natally lethal. Biochem Biophys Res Commun 362 (2007) 387-392
18. Wu D, Mennerich D, Arndt K, et al. The effects of microsomal prostaglandin E synthase-1 deletion in acute cardiac ischemia in mice. Prostaglandins Leukot Essent Fatty Acids. 2009 Jun 11. [Epub ahead of print].
19. Uematsu S., Matsumoto M., Takeda K., and Akira S. Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway. J Immunol 168 (2002) 5811-5816
20. Solomon S.D., Wittes J., Finn P.V., et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117 (2008) 2104-2113
21. Smith W.L. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 263 (1992) F181-191
22. Gerritsen M.E. Physiological and pathophysiological roles of eicosanoids in the microcirculation. Cardiovasc Res 32 (1996) 720-732
23. Morham S.G., Langenbach R., Loftin C.D., et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83 (1995) 473-482
24. Camitta M.G., Gabel S.A., Chulada P., et al. Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. Circulation 104 (2001) 2453-2458
25. Mukherjee D., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 (2001) 954-959
26. Graham D.J., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 (2005) 475-481
27. Brenneis C., Coste O., Schmidt R., et al. Consequences of altered eicosanoid patterns for nociceptive processing in mPGES-1-deficient mice. J Cell Mol Med 12 (2008) 639-648
28. de Leval X., Hanson J., David J.L., et al. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. Curr Med Chem 11 (2004) 1243-1252
29. Xiao C.Y., Hara A., Yuhki K., et al. Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 104 (2001) 2210-2215
30. Hara A., Yuhki K., Fujino T., et al. Augmented cardiac hypertrophy in response to pressure overload in mice lacking the prostaglandin I2 receptor. Circulation 112 (2005) 84-92
31. LaPointe M.C., Mendez M., Leung A., Tao Z., and Yang X.P. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol Heart Circ Physiol 286 (2004) H1416-H1424
32. Båge T., Modéer T., Kawakami T., Quezada H.C., and Yucel-Lindberg T. Regulation of prostaglandin E synthases: effects of siRNA-mediated inhibition of microsomal prostaglandin E synthase-1. Biochim Biophys Acta 1773 (2007) 1589-1598
33. Giannico G., Mendez M., and LaPointe M.C. Regulation of the membrane-localized prostaglandin E synthases mPGES-1 and mPGES-2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol 288 (2005) H165-174
34. Elander N., Ungerbäck J., Olsson H., Uematsu S., Akira S., and Söderkvist P. Genetic deletion of mPGES-1 accelerates intestinal tumorigenesis in APC(Min/+) mice. Biochem Biophys Res Commun 18 372 (2008) 249-253
35. Tanioka T., Nakatani Y., Semmyo N., Murakami M., and Kudo I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 275 (2000) 32775-32782
36. Mendez M., and LaPointe M.C. Trophic effects of the cyclooxygenase-2 product prostaglandin E(2) in cardiac myocytes. Hypertension 39 (2002) 382-388
37. Murakami M., Nakashima K., Kamei D., et al. Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J Biol Chem 278 (2003) 37937-37947
38. Dinchuk J.E., Car B.D., Focht R.J., et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378 (1995) 406-409
39. Yokoyama C., Yabuki T., Shimonishi M., et al. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation 106 (2002) 2397-2403